Certain Common Stock of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
June 18, 2024
Share
Certain Common Stock of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024. These Common Stock will be under lockup for 46 days starting from 3-MAY-2024 to 18-JUN-2024.
Details:
The company has agreed that, for a period of forty-five (45) days after the close of this offering, without the prior written consent of the underwriter, and subject to certain exceptions, neither the company nor any of its subsidiaries shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents or file any registration statement or amendment or supplement thereto, other than this prospectus supplement or a registration statement on Form S-8.
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
AILERON THERAPEUTICS, INC. 
